SignalXSignalX

Alnylam Pharmaceuticals (ALNY) 8-K Current Report: March 4, 2026

Filed: March 4, 2026
Health Care
Pharmaceutical Preparations
Alnylam Pharmaceuticals Overview

Alnylam Pharmaceuticals (ALNY) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.02: Departure/Election of Directors or Officers

Alnylam Pharmaceuticals 8-K Mar 4, 2026 Event Analysis

Item 5.02 · Departure/Election of Directors or Officers

  • • CEO Dr. Greenstreet granted 55,373 target PSUs on March 2, 2026 with face value of $18.0M at $325.07/share
  • • 100% performance-based; minimum threshold $500/share (~54% above grant date price) must be met or award forfeits entirely
  • • Payout range: 50% of target at $500/share up to 200% of target (110,746 shares) at $800/share — all by Dec 31, 2029
  • • Baseline threshold exceeds ALNY all-time high as of grant date — a meaningful retention/alignment tool tied to substantial new value creation
  • • Board explicitly frames award as retention anchor for "Alnylam 2030" five-year plan, following ~100% stockholder return under Greenstreet's prior tenure

Get deeper insights on Alnylam Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.